Showing results (41-50 of 66) with videos related to

Sort By:
Pageof 7
Japanese Journal of Clinical Oncology|December 20, 2024
Clinical outcomes of patients with EGFR-mutated NSCLC developing interstitial lung disease during first-line osimertinib therapy: a sub-analysis of the Reiwa studyTakayuki Kobayashi, Kageaki Watanabe, Yukio Hosomi, et al.
Japanese Journal of Clinical Oncology|December 20, 2024
Observational study of the efficacy and safety of first-line osimertinib and later treatments for uncommon epidermal growth factor receptor-activating mutation-positive advanced non-small cell lung cancerTsuyoshi Hirata, Kageaki Watanabe, Yukio Hosomi, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 7, 2002
Targeting angiogenesis and HGF function using an adenoviral vector expressing the HGF antagonist NK4 for cancer therapyMakoto Maemondo, Ko Narumi, Yasuo Saijo, et al.
Lung Cancer (Amsterdam, Netherlands)|November 27, 2024
Difference in efficacy of osimertinib between patients with EGFR-positive NSCLC with postoperative recurrence and those with de novo unresectable disease: A prospective, observational studyMasato Karayama, Takafumi Suda, Kiyotaka Yoh, et al.
Oncogene|May 6, 2003
N-terminal deletion augments the cell-death-inducing activity of BAX in adenoviral gene delivery to nonsmall cell lung cancersKazuhiro Usui, Yasuo Saijo, Ko Narumi, et al.
Thoracic Cancer|December 7, 2024
Real-World Study of EGFR-TKI Rechallenge With Another TKI After First-Line Osimertinib Discontinuation in Patients With EGFR-Mutated Non-Small Cell Lung Cancer: A Subset Analysis of the Reiwa StudyKei Sonehara, Kazunari Tateishi, Kiyotaka Yoh, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 22, 2002
Proinflammatory cytokine IL-1 beta promotes tumor growth of Lewis lung carcinoma by induction of angiogenic factors: in vivo analysis of tumor-stromal interactionYasuo Saijo, Masashi Tanaka, Makoto Miki, et al.
BMC Cancer|March 2, 2021
A phase II study of first-line afatinib for patients aged ≥75 years with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan Study Group trial NEJ027Yuji Minegishi, Ou Yamaguchi, Shunichi Sugawara, et al.
Cancer Research|July 3, 2004
Gene therapy with secretory leukoprotease inhibitor promoter-controlled replication-competent adenovirus for non-small cell lung cancerMakoto Maemondo, Yasuo Saijo, Ko Narumi, et al.
Japanese Journal of Clinical Oncology|November 15, 2017
Effect of sequential chemoradiotherapy in patients with limited-disease small-cell lung cancer who were ineligible for concurrent therapy: a retrospective study at two institutionsSayaka Ohara, Shintaro Kanda, Hitomi Okuma, et al.
Pageof 7